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Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2
(HER2) have been considered as potential therapeutic targets in cholangiocarcinoma, but no studies have yet clarified the
clinicopathological or prognostic significance of these molecules. Immunohistochemical expression of these molecules was assessed
retrospectively in 236 cases of cholangiocarcinoma, as well as associations between the expression of these molecules and
clinicopathological factors or clinical outcome. The proportions of positive cases for EGFR, VEGF, and HER2 overexpression were
27.4, 53.8, and 0.9% in intrahepatic cholangiocarcinoma (IHCC), and 19.2, 59.2, and 8.5% in extrahepatic cholangiocarcinoma
(EHCC), respectively. Clinicopathologically, EGFR overexpression was associated with macroscopic type (P¼0.0120), lymph node
metastasis (P¼0.0006), tumour stage (P¼0.0424), lymphatic vessel invasion (P¼0.0371), and perineural invasion (P¼0.0459) in
EHCC, and VEGF overexpression with intrahepatic metastasis (P¼0.0224) in IHCC. Multivariate analysis showed that EGFR
expression was a significant prognostic factor (hazard ratio (HR), 2.67; 95% confidence interval (CI), 1.52–4.69; P¼0.0006) and also
a risk factor for tumour recurrence (HR, 1.89; 95% CI, 1.05–3.39, P¼0.0335) in IHCC. These results suggest that EGFR expression is
associated with tumour progression and VEGF expression may be involved in haematogenic metastasis in cholangiocarcinoma.
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Cholangiocarcinoma arises from the ductal epithelium of the bile
duct tree and is classified anatomically into intrahepatic cholangio-
carcinoma (IHCC) and extrahepatic cholangiocarcinoma (EHCC).
The incidence and mortality rates of cholangiocarcinoma, especially
those of IHCC, are increasing worldwide (Khan et al, 2005).
Complete resection is the only way to cure the disease at present.
Moreover, because cholangiocarcinoma is difficult to diagnose at
an early stage and extends diffusely, most patients have
unresectable disease at clinical presentation, and prognosis is very
poor (5-year survival is 0–40% even in resected cases) (Khan et al,
2005; Sirica, 2005). Therefore, novel effective therapeutic strategies
are urgently required to improve the prognosis. Among potential
therapeutic targets, several studies have revealed overexpression of
epidermal growth factor receptor (EGFR) or human epidermal
growth factor receptor 2 (HER2) protein, amplification, and
mutation of these genes (Ito et al, 2001; Aishima et al, 2002;
Ukita et al, 2002; Altimari et al, 2003; Gwak et al, 2005; Nakazawa
et al, 2005; Leone et al, 2006) as well as overexpression of vascular
endothelial growth factor (VEGF) protein (Hida et al, 1999; Tang
et al, 2006) in cholangiocarcinoma.
Epidermal growth factor receptor and HER2 are members of the
ErbB receptor tyrosine kinase family. Binding of ligands, such as
epidermal growth factor and transforming growth factor alpha
(TGFa), to their extracellular ligand-binding domain initiates
intracellular signalling cascades, leading to progression, prolifera-
tion, migration, and survival of cancer cells (Olayioye et al, 2000;
Yarden and Sliwkowski, 2001). Vascular endothelial growth factor
plays a key role in tumour-associated neo-angiogenesis, which
contributes to providing a tumour with oxygen, nutrition, and a
route for metastasis. It binds to VEGFR (vascular endothelial
growth factor receptor), and leads to survival, proliferation, and
migration of endothelial cell (Tabernero, 2007). Expression of
these molecules has been reported to have prognostic significance
in several cancers (Gusterson et al, 1992; Han et al, 2001;
Nicholson et al, 2001; Des Guetz et al, 2006; Mohammed et al,
2007). Recently, agents targeted at these molecules have been used
clinically, such as trastuzumab in breast cancer (Gonzalez Angulo
et al, 2006), gefitinib, and erlotinib in non-small cell lung cancer,
and bevacizumab in colorectal cancer (Tabernero, 2007). In
cholangiocarcinoma, a phase II study of erlotinib (Philip et al,
2006) and some case reports of combined chemotherapy including
cetuximab (Sprinzl et al, 2006; Huang et al, 2007) have been
reported.
However, no previous studies have clarified associations
between the expression of these molecules and clinicopathological
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sfactors or prognosis in patients with cholangiocarcinoma. To
elucidate the biological significance and potential of these
molecules as therapeutic targets, we investigated EGFR/VEGF/
HER2 expression and attempted to elucidate their associations
with various clinical features as well as patient survival in 236 cases
of cholangiocarcinomas.
MATERIALS AND METHODS
Patients
A total of 236 patients with cholangiocarcinoma (male 160; female
76) who had undergone tumour resection and been diagnosed
histologically as having adenocarcinoma of the bile duct at the
National Cancer Center Hospital, Tokyo, between January 1991
and August 2004, were enrolled in the present study. Median
patient age and follow-up period were 65 years and 875 days, and
median tumour sizes of IHCC and EHCC were 4.8 and 3.0cm,
respectively. Detailed characteristics of patient with IHCC and
EHCC are presented in Tables 1 and 2. All patients were followed
for more than 100 days. Follow-up examination was performed
using computed tomography, abdominal ultrasonography, and
measurement of the serum carcinoembryonic antigen and
carbohydrate antigen 19–9 (CA19-9) levels every 3–6 months.
Recurrence was diagnosed by clinical, radiological, or pathological
methods, but mainly by radiological evaluation including computed
tomography and ultrasonography. Clinical and pathological
profiles were obtained from the database of hepatobiliary tumours
based on the medical records of the patients. This study was
approved by the Ethics Committee of the National Cancer Center,
Tokyo, Japan, and written informed consent was obtained from all
patients.
All cases were anatomically classified into two groups: IHCC and
EHCC. Tumours arising from the bilateral hepatic duct or distal
common bile duct were classified as EHCC. The numbers of IHCC
and EHCC cases were 106 and 130, respectively.
Histological assessment
Tumour staging and histological classification were assessed
according to TNM Classification of Malignant Tumours (Sobin
and Wittekind, 2002) defined by the International Union Against
Cancer (UICC) and the World Health Organization Histological
Classification of Tumours (Hamilton and Altonen, 2000). Macro-
scopic types of IHCC were defined with reference to General Rules
for the Clinical and Pathological Study of Primary Liver Cancer
(Liver Cancer Study Group of Japan, 2003): (1) the mass-forming
type (MF), which develops an apparent tumour in the liver; (2) the
periductal infiltrating type (PI), which spreads along the bile duct;
(3) the intraductal growth type (IG), which is confined within the
bile duct, and divided into two groups: the mass-forming group
(MF and MF mixed with PI or IG) and the non-mass forming
group (PI and/or IG). Macroscopic types of EHCC were divided
into polypoid type and non-polypoid type (including nodular,
scirrhous constricting, and infiltrating types). Other clinicopatho-
logical factors were categorised into groups that are presented in
Table 1 (IHCC) and Table 2 (EHCC). Because the classifications
and clinicopathological factors used in IHCC and EHCC are
different, statistical analyses were performed separately.
Immunohistochemistry
Immunohistochemistry (IHC) for EGFR, VEGF, and HER2 was
performed using a polymer-based method (EnvisiontþDual Link
System-HRP (Dako, DK-2600 Glostrup, Denmark)). Sources and
dilutions of primary antibodies were as follows: anti-EGFR (mouse
monoclonal, clone 31G7; Zymed, South San Francisco, CA, USA;
1:100), anti-VEGF (rabbit polyclonal; Zymed; 1:50), and anti-
HER2 (rabbit polyclonal; Dako; 1:300).
Formalin-fixed, paraffin-embedded serial tissue sections (4mm)
were placed on silane-coated slides for IHC. Sections cut through
the maximum tumour diameter were selected for IHC evaluation.
The sections were deparaffinised and rehydrated in xylene and
grade-diluted ethanol (50–100%), and submerged for 20min in
0.3% hydrogen peroxide with absolute methanol to block
endogenous peroxidase activity. Antigen retrieval for EGFR, VEGF,
and HER2 was carried out by adding Digest-allt3 pepsin solution
(Zymed) at 371C for 10min for EGFR, near boiling in 0.01M citrate
buffer (pH 6.0) for 15min for VEGF, and heating in 0.01M citrate
buffer at 1211C for 10min by pressure cooker for HER2. After
protein blocking, the sections were incubated with each primary
antibody at room temperature for 1h, followed by incubation with
Table 1 Characteristics of the IHCC patients
Factors Categories Population
Age o65 years old 54 (50.9%)
X65 years old 52 (49.1%)
Gender Male 64 (60.4%)
Female 42 (39.6%)
Tumour size p5.0cm 55 (55.6%)
45.0cm 44 (44.4%)
Macroscopic type Non-mass forming 17 (16.0%)
Mass forming 89 (84.0%)
Invasion of portal vein Negative 23 (21.9%)
Positive 82 (78.1%)
Invasion of hepatic vein Negative 56 (54.9%)
Positive 46 (45.1%)
Intrahepatic metastasis Negative 75 (70.8%)
Positive 31 (29.2%)
Lymph node metastasis Negative 62 (58.5%)
Positive 44 (41.5%)
UICC pT 1+2 71 (68.3%)
3+4 33 (31.7%)
UICC stage 1+2 45 (42.5%)
3A+3B+3C 61 (57.5%)
Histological classification Well 22 (20.8%)
Mod 79 (74.5%)
Por 5 (4.7%)
Lymphatic vessel invasion Negative 20 (18.9%)
Positive 86 (81.1%)
Venous invasion Negative 19 (17.9%)
Positive 87 (82.1%)
Perineural invasion Negative 29 (27.4%)
Positive 77 (72.6%)
Hepatic surgical margin Negative 89 (84.0%)
Positive 17 (16.0%)
Bile duct margin Negative 91 (85.8%)
Positive 15 (14.2%)
Well¼well differentiated adenocarcinoma; Mod¼moderately differentiated adeno-
carcinoma; Por¼poorly differentiated adenocarcinoma. In some factors, data were
not available for all cases.
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and visualised using 3,30-diaminobenzidine tetrahydrochloride as
a chromogen. Finally, the sections were counterstained with
haematoxylin. Sections were gently rinsed in phosphate-buffered
saline between the incubation steps.
Evaluation of immunohistochemistry
All sections were evaluated by DY, HO, and TS without the
knowledge of any clinical or pathological information, and cases
for which consensus could not be reached were discussed to decide
the evaluation. Based on the Herceptestt (Dako) criteria,
intensities of both EGFR and HER2 were defined as follows: 0,
no membrane staining or membrane staining in p10% cancer
cells; 1þ, faint and partial membrane staining in 410% cancer
cells; 2þ, moderate and complete membrane staining in 410%
cancer cells; 3þ, strong and complete membrane staining in
410% cancer cells. Intensities of VEGF were defined as follows: 0,
no cytoplasmic staining or cytoplasmic staining in p30% cancer
cells; 1þ, faint cytoplasmic staining, equivalent to the intensity of
normal bile duct epithelium within the same section, in 430%
cancer cells; 2þ, moderate cytoplasmic staining in 430% cancer
cells; 3þ, strong cytoplasmic staining in 430% cancer cells. For
cases showing mixed intensity, the predominant intensity was
selected as the final IHC score. A final IHC score of 2þ or 3þ was
defined as positive for expression of each protein.
Statistical analysis
Associations between results of IHC and clinicopathological
factors were assessed by w
2 test. Cumulative survival rates and
survival curves were calculated by the Kaplan–Meier method, and
log-rank test was performed for the comparison of survival curves.
Cox’s proportional hazard model was performed to estimate
hazard ratio (HR) and 95% confidence interval (CI) of each
outcome (death and recurrence). Multivariate analyses were
performed using the factors identified to be risk factors for each
outcome by univariate analyses, without UICC pT and UICC Stage,
which are composed of other factors. All P-values reported are
two-sided, and significance level was set at Po0.05. All statistical
analyses were performed with the Statview 5.0 statistical software
package (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Expression of EGFR, VEGF, and HER2 protein in
cholangiocarcinoma
Representative cases of positive staining for each protein are
shown in Figure 1 (A, EGFR; B, HER2; C, VEGF). Epidermal
growth factor receptor, VEGF, and HER2 were expressed in 29
(27.4), 57 (53.8), and 1 (0.9%) of the 106 IHCCs, respectively, and
in 25 (19.2), 77 (59.2), and 11 (8.5%) of the 130 EHCCs,
respectively. Microscopically, EGFR was mostly overexpressed in
the moderately and/or poorly differentiated component, which is
characterised by infiltration (52 of 54 EGFR-positive cases,
Figure 1D), whereas only two cases showed EGFR overexpression
in the well-differentiated component. In contrast, HER2 was
preferentially expressed in the well-differentiated component. In
6 of 12 HER2-positive cases, HER2 was expressed only in
well-differentiated component (Figure 1E), and 5 progressive cases
showed positive HER2 staining in both the well and moderately
and/or poorly differentiated components and 1 case only in
moderately differentiated component. There was no association
between VEGF expression and histological features.
Associations between EGFR, VEGF, and HER2 expression
and clinocopathological factors
Statistical analyses of HER2 were performed only in EHCC cases
because of the small number of HER2-positive cases in IHCC. In
IHCC, VEGF expression was significantly associated with intra-
hepatic metastasis (P¼0.0224). There was no significant association
between EGFR expression and any clinicopathological factors.
In EHCC, EGFR expression was significantly associated with
macroscopic type (0% in the polypoid type, 24.0% in the non-
polypoid type; P¼0.0120), lymph node metastasis (P¼0.0006),
UICC Stage (P¼0.0424), lymphatic vessels invasion (P¼0.0371),
and perineural invasion (P¼0.0459). Human epidermal growth
factor receptor 2 expression was significantly associated with
Table 2 Characteristics of the EHCC patients
Factors Categories Population
Age o65 years old 60 (46.2%)
X65 years old 70 (53.8%)
Gender Male 96 (73.8%)
Female 34 (26.2%)
Tumour size p3.0cm 72 (56.3%)
43.0cm 56 (43.7%)
Macroscopic type Polypoid 21 (16.8%)
Non-polypoid 104 (83.2%)
Depth of tumour invasion Within FM 13 (10.0%)
Beyond FM 117 (90.0%)
Invasion of portal vein Negative 97 (74.6%)
Positive 33 (25.4%)
Invasion of hepatic artery Negative 127 (97.7%)
Positive 3 (2.3%)
Lymph node metastasis Negative 71 (54.6%)
Positive 59 (45.4%)
UICC pT 1+2 49 (37.7%)
3+4 81 (62.3%)
UICC stage 1A+1B 37 (28.5%)
2A+2B+C 93 (71.5%)
Histological classification Pap 20 (15.4%)
Well 31 (23.8%)
Mod 62 (47.7%)
Por 17 (13.1%)
Lymphatic vessel invasion Negative 16 (12.3%)
Positive 114 (87.7%)
Venous invasion Negative 19 (14.6%)
Positive 111 (85.4%)
Perineural invasion Negative 23 (17.7%)
Positive 107 (82.3%)
Dissected periductal structures margin Negative 109 (83.8%)
Positive 21 (16.2%)
Bile duct margin Negative 92 (70.8%)
Positive 38 (29.2%)
Invasion to other organ Negative 53 (40.8%)
Positive 77 (59.2%)
FM¼fibromuscular layer; Pap¼papillary adenocarcinoma; Well¼well differentiated
adenocarcinoma; Mod¼moderately differentiated adenocarcinoma; Por¼poorly
differentiated adenocarcinoma. In some factors, data were not available for all cases.
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smacroscopic type (23.8% in the polypoid type, 5.8% in the non-
polypoid type; P¼0.0078), histological classification (25% in
papillary adenocarcinoma, 9.7% in well differentiated adenocarci-
noma, 3.2% in moderately differentiated adenocarcinoma, 5.9% in
poorly differentiated adenocarcinoma; P¼0.0237), and invasion to
other organs (3.9% in invasive cases, 15.1% in non-invasive cases;
P¼0.0242). VEGF expression was not significantly associated with
any factors in EHCC.
Detailed results of associations between EGFR/VEGF/HER2
expression and clinicopathological factors are shown in Supple-
mentary information 1 (IHCC) and Supplementary information 2
(EHCC).
Univariate and multivariate analyses regarding overall
survival and tumour recurrence in cholangiocarcinoma
The number of dead and the median survival time were 70 cases
and 724 days in IHCCs, and 76 cases and 1197 days in EHCCs,
respectively. The number of recurrence and the median recurrence
time were 64 cases and 522 days in IHCCs, and 78 cases and 960
days in EHCCs, respectively.
Overall 5-year cumulative survival for patients with IHCC and
EHCC was 33.0 and 41.6%, respectively, and no significant
difference was identified between the groups (P¼0.0599). The
survival curves stratified by EGFR expression status are shown as
Figure 2. Five-year survival for patients with EGFR-positive and
EGFR-negative tumours was 17.7 and 47.1% for IHCC, and 26.4
and 45.6% for EHCC, respectively. There was a significant
difference between EGFR-positive and -negative cases for both
IHCC (P¼0.0008) and EHCC (P¼0.0204).
The results of multivariate analyses following univariate
analyses regarding overall survival and tumour recurrence are
shown in Table 3 (IHCC) and Table 4 (EHCC).
In IHCC, 13 factors including EGFR expression were identified
as significantly prognostic by univariate analysis. Multivariate
analysis revealed that EGFR expression was an independent
prognostic factor (HR, 2.67; 95% CI, 1.52–4.69; P¼0.0006), along
with mass-forming macroscopic group (HR, 2.96; 95% CI, 1.06–
8.31; P¼0.0390), intrahepatic metastasis (HR, 2.91; 95% CI, 1.60–
5.29; P¼0.0005), and lymph node metastasis (HR, 1.96; 95% CI,
1.04–3.69; P¼0.0375). In EHCC, 14 factors including EGFR
expression were identified as significantly prognostic by univariate
analysis. Multivariate analysis revealed that lymph node metastasis
(HR, 2.03; 95% CI, 1.16–3.55; P¼0.0133) and a histological
classification of moderately differentiated adenocarcinoma (HR for
papillary adenocarcinoma, 4.23; 95% CI, 1.08–16.50; P¼0.0380)
and poorly differentiated adenocarcinoma (HR for papillary
adenocarcinoma, 13.22; 95% CI, 3.10–56.45; P¼0.0005) were
significant prognostic factors.
Multivariate analysis following univariate analysis for risk
factors of tumour recurrence revealed that EGFR expression in
IHCC was a significant risk factor of tumour recurrence (HR, 1.89;
AB
E
CD
Figure 1 Representative immunohistochemical staining of (A) EGFR, (B) HER2, and (C) VEGF in cholangiocarcinoma ( 400 magnification). (D)
Epidermal growth factor receptor tends to be expressed in the poorly differentiated component ( 100 magnification). (E) Human epidermal growth factor
receptor 2 is preferentially expressed in more differentiated areas such as the glandular or papillary component ( 100 magnification).
EGFR, VEGF, HER2 in cholangiocarcinoma
D Yoshikawa et al
421
British Journal of Cancer (2008) 98(2), 418–425 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s95% CI, 1.05–3.39; P¼0.0335), along with intrahepatic metastasis
(HR, 2.36; 95% CI, 1.31–4.25; P¼0.0044), lymph node metastasis
(HR, 2.24; 95% CI, 1.19–4.22; P¼0.0126), and venous invasion
(HR, 6.74; 95% CI, 1.31–34.73; P¼0.0225), whereas, in EHCC,
lymph node metastasis (HR, 1.75; 95% CI, 1.03–2.98; P¼0.0394)
and dissected periductal structures margin (HR, 1.81; 95% CI,
1.03–3.16; P¼0.0383) were independent risk factors of tumour
recurrence, but EGFR expression was not associated with tumour
recurrence even in univariate analysis.
DISCUSSION
This study, analysing EGFR/VEGF/HER2 expression in the largest
cohort of cholangiocarcinoma reported so far, showed for the first
time that EGFR expression in IHCC is significantly associated
with poor prognosis. In addition, our study confirmed previously
reported prognostic factors in cholangiocarcinoma, such as
macroscopic type, intrahepatic metastasis, lymph node metastasis,
and histological classification (Yamamoto et al, 1998; Ohtsuka
et al, 2002; Morimoto et al, 2003; DeOliveira et al, 2007).
Expression of EGFR or HER2 is known to be a prognostic factor
in some cancers (Gusterson et al, 1992; Nicholson et al, 2001), but
no previous study has clarified the influence of these molecules on
prognosis in cholangiocarcinoma (Ito et al, 2001; Altimari et al,
2003; Nakazawa et al, 2005), probably because cholangiocarcinoma
is a relatively rare cancer and collection of a large cohort is
difficult. Indeed, most previous studies were performed on the
basis of only 50 cases at most. Although it is unclear why EGFR
expression in IHCC is an independent prognostic factor, it may be
associated with frequent relapse of cancer because EGFR expres-
sion is also a risk factor for tumour recurrence.
In contrast to IHCC, EGFR expression was not an independent
prognostic factor in EHCC, but was associated with clinical
features that may represent tumour progression and invasion,
such as lymph node metastasis and apparent stromal invasion in
EHCC. Because cancer tissue tends to be heterogeneous,
histological diagnosis is generally decided on the basis of the
degree of differentiation that predominates. In order to elucidate
the biological significance of each protein, we microscopically
examined positive cases in detail and compared their expression
with histological components, and found that EGFR tended to
be expressed in the poorly differentiated component, which is
characterised by infiltration in both IHCC and EHCC. Similar
results have been reported in bladder cancer (Neal et al, 1985),
oesophageal adenocarcinoma (Wilkinson et al, 2004), and IHCC
(Ito et al, 2001), although the studies were based on small cohorts.
These findings indicate that EGFR expression may be a relatively
late event in the development of cholangiocarcinoma and
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Figure 2 Survival curves stratified by EGFR expression in (A) IHCC and
(B) EHCC (Kaplan–Meier method). The outcome of EGFR-positive cases
was significantly worse than that of EGFR-negative cases in both IHCC
(P¼0.0008) and EHCC (P¼0.0204) (by log-rank test).
Table 3 Multivariate analyses regarding overall survival and tumour
recurrence in IHCC (Cox’s proportional hazard model)
Overall survival Tumour recurrence
HR 95% CI P-value HR 95% CI P-value
Macroscopic type
Non-mass forming 1.00 1.00
Mass forming 2.96 1.06–8.31 0.0390 3.06 1.00–9.40 0.0505
Invasion of portal vein
Negative 1.00 1.00
Positive 0.67 0.30–1.47 0.31 1.01 0.43–2.41 0.98
Invasion of hepatic vein
Negative 1.00 1.00
Positive 1.19 0.66–2.12 0.57 1.17 0.65–2.14 0.60
Intrahepatic metastasis
Negative 1.00 1.00
Positive 2.91 1.60–5.29 0.0005 2.36 1.31–4.25 0.0044
Lymph node metastasis
Negative 1.00 1.00
Positive 1.96 1.04–3.69 0.0375 2.24 1.19–4.22 0.0126
Histological classification
Well differentiated 1.00 1.00
Moderately
differentiated
1.24 0.56–2.75 0.60 0.65 0.28–1.53 0.32
Poorly differentiated 2.09 0.58–7.49 0.26 1.35 0.32–5.72 0.69
Lymphatic vessel invasion
Negative 1.00 1.00
Positive 3.31 0.80–13.65 0.0982 1.37 0.41–4.56 0.61
Venous invasion
Negative 1.00 1.00
Positive 4.07 0.97–17.09 0.0551 6.74 1.31–34.73 0.0225
Perineural invasion
Negative 1.00 —
Positive 0.60 0.26–1.36 0.22 — — —
Bile duct margin
Negative 1.00 —
Positive 1.84 0.91–3.73 0.0923 — — —
EGFR expression
Negative 1.00 1.00
Positive 2.67 1.52–4.69 0.0006 1.89 1.05–3.39 0.0335
Abbreviations: CI¼confidence interval; HR¼hazard ratio.
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previously reported that poor differentiation is associated with
unfavourable outcome in other cancers (Sohn et al, 2000; Hassan
et al, 2005), the association between EGFR expression and poor
differentiation may also be a reason that EGFR expression is a
prognostic factor.
Though the prognostic factors were different between IHCC
and EHCC, it may be due to the difference of anatomical
character, which extrahepatic bile duct is near from other organs
and is not surrounded by liver parenchyma in contrast to
intrahepatic bile duct. The intrahepatic epithelium is distinct from
the extrahepatic epithelium in terms of development and
differentiation (Shiojiri, 1997), and the risk factors, pathogenesis,
and clinical features of IHCC and EHCC are different (Strom et al,
1985; Nakeeb et al, 1996; Shaib et al, 2007). Although no previous
studies have elucidated EGFR function in normal bile duct
epithelium, EGFR overexpression might play distinct roles in
IHCC and EHCC.
Vascular endothelial growth factor expression was detected
frequently, being evident in about 60% of our study cases, which is
consistent with previous studies (31.4–75.6%) (Hida et al, 1999;
Tang et al, 2006). Our study revealed that VEGF expression was
significantly associated with intrahepatic metastasis in IHCC.
Vascular endothelial growth factor is a key molecule in angiogenic
pathway. Angiogenesis is an essential component in the process of
metastasis, and this has been partly confirmed by studies showing
that microvessel density (MVD) is associated with metastasis and a
poorer outcome in a range of cancers (Weidner et al, 1991; Zetter,
1998). It has also been reported that high MVD is an independent
prognostic factor in node-negative IHCC (Shirabe et al, 2004) and
is associated with VEGF expression in IHCC (Tang et al, 2006),
although no study has clarified the involvement of angiogenesis in
the process of metastasis in cholangiocarcinoma. Our result
suggests that VEGF plays an important role in the process of
cholangiocarcinoma metastasis by promoting angiogenesis.
Human epidermal growth factor receptor 2 was expressed in
only 11 of 130 EHCC cases (8.5%) and in one of 106 IHCC cases
(0.9%). The proportion of HER2-positive cases reported previously
has varied from 4.2 to 81.8% (Ito et al, 2001; Aishima et al, 2002;
Ukita et al, 2002; Altimari et al, 2003; Nakazawa et al, 2005), and
the discrepancy may be due to differences in staining procedure or
tumour location. In contrast to EGFR expression, HER2 expression
was associated with more favourable clinical features, such as a
polypoid macroscopic type and absence of other organ involve-
ment. The proportion of HER2-positive cases in papillary
adenocarcinoma was higher than in other histological types,
consistent with some previous reports claiming that HER2
expression in cholangiocarcinoma is associated with an early
disease stage (Endo et al, 2002; Nakazawa et al, 2005).
Microscopically, HER2 is preferentially expressed in well differ-
entiated component, and it is also expressed in dedifferentiated
components (moderately and/or poorly differentiated components)
in progressive cases. This indicates that HER2 overexpression is
maintained from an early stage of carcinogenesis in cases that are
HER2-positive.
Recently, the efficacy of molecular targeting therapy for various
molecules including EGFR/VEGF/HER2 has been proved clinically
in a wide range of cancers. Epidermal growth factor receptor
inhibitor has been reported to be effective in a cholangiocarcinoma
cell line (Yoon et al, 2004), and a phase II study of erlotinib, an
EGFR inhibitor, in patients with advanced biliary cancer has been
reported. In this study, the progression-free rate at 6 months as a
primary end point was 17% (7/42) despite the fact that disease
condition was severe, and the disease control rate was 50% (20/42)
(Philip et al, 2006). This study suggested the clinical applicability
of the EGFR inhibitor to cholangiocarcinoma. Several clinical trials
demonstrating the efficacy of VEGF inhibition for other cancers
have been reported (Hurwitz et al, 2004; Sandler et al, 2006),
and VEGF upregulation in tumour cells is considered to be a
mechanism of resistance to EGFR inhibitors (Viloria Petit et al,
2001). Therefore, dual inhibition of both EGFR and VEGF may
exert a synergistic effect.
In summary, we have shown that EGFR and VEGF expression is
relatively common in cholangiocarcinoma. Moreover, in IHCC,
EGFR expression is an independent prognostic factor and VEGF
expression is associated with intrahepatic metastasis. In EHCC,
EGFR expression is associated with clinical factors involved in
tumour progression and invasion. Our results suggest the validity and
significance of molecular targeting agents for EGFR and/or VEGF
pathway, and that further preclinical and clinical studies are
warranted for improving the clinical outcome of cholangiocarcinoma.
Table 4 Multivariate analyses regarding overall survival and tumour
recurrence in EHCC (Cox’s proportional hazard model)
Overall survival Tumour recurrence
HR 95% CI P-value HR 95% CI P-value
Tumour size
p3.0cm 1.00 —
43.0cm 1.29 0.71–2.35 0.41 — — —
Macroscopic type
Polypoid 1.00 —
Non-polypoid 0.44 0.16–1.26 0.13 — — —
Depth of tumour invasion
Within FM 1.00 1.00
Beyond FM 1.26 0.19–8.60 0.81 1.16 0.24–5.57 0.85
Invasion of portal vein
Negative 1.00 1.00
Positive 1.48 0.81–2.69 0.20 1.59 0.92–2.75 0.94
Lymph node metastasis
Negative 1.00 1.00
Positive 2.03 1.16–3.55 0.0133 1.75 1.03–2.98 0.0394
Histological classification
Papillary 1.00 1.00
Well differentiated 3.40 0.85–13.66 0.0849 0.91 0.33–2.51 0.85
Moderately
differentiated
4.23 1.08–16.50 0.0380 1.19 0.47–3.02 0.72
Poorly differentiated 13.22 3.10–56.45 0.0005 2.80 0.99–7.87 0.0516
Lymphatic vessel invasion
Negative 1.00 1.00
Positive 1.78 0.29–11.10 0.54 2.36 0.45–12.37 0.31
Venous invasion
Negative 1.00 1.00
Positive 3.93 0.81–19.12 0.0898 1.89 0.52–6.92 0.34
Perineural invasion
Negative 1.00 1.00
Positive 1.94 0.58–6.53 0.29 0.98 0.38–2.51 0.97
Dissected periductal structures margin
Negative 1.00 1.00
Positive 1.20 0.67–2.17 0.54 1.81 1.03–3.16 0.0383
Invasion to other organ
Negative 1.00 1.00
Positive 1.02 0.53–1.94 0.96 0.94 0.53–1.69 0.84
EGFR expression
Negative 1.00 —
Positive 1.04 0.55–1.96 0.90 — — —
HR¼hazard ratio; CI¼confidence interval; FM¼fibromuscular layer.
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